Quantbot Technologies LP Trims Stake in Zoetis Inc. $ZTS

Quantbot Technologies LP lessened its holdings in Zoetis Inc. (NYSE:ZTS) by 43.8% during the third quarter, HoldingsChannel reports. The institutional investor owned 15,573 shares of the company’s stock after selling 12,136 shares during the quarter. Quantbot Technologies LP’s holdings in Zoetis were worth $2,279,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after purchasing an additional 2,978 shares in the last quarter. Empowered Funds LLC raised its stake in Zoetis by 6.2% in the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after purchasing an additional 657 shares in the last quarter. Intech Investment Management LLC lifted its position in Zoetis by 17.2% during the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after purchasing an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC grew its stake in Zoetis by 73.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after buying an additional 1,422 shares in the last quarter. Finally, Assetmark Inc. increased its holdings in shares of Zoetis by 12.2% in the 2nd quarter. Assetmark Inc. now owns 26,409 shares of the company’s stock worth $4,119,000 after buying an additional 2,876 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ZTS. Bank of America raised their price objective on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. The Goldman Sachs Group raised Zoetis to a “buy” rating in a research note on Monday, December 15th. HSBC set a $140.00 price target on Zoetis in a research note on Wednesday, December 10th. Morgan Stanley set a $160.00 price objective on Zoetis in a report on Thursday, December 18th. Finally, UBS Group set a $136.00 price objective on Zoetis in a report on Thursday, January 29th. Six research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Zoetis currently has a consensus rating of “Hold” and an average target price of $152.91.

Zoetis Price Performance

Shares of Zoetis stock opened at $126.01 on Wednesday. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. Zoetis Inc. has a one year low of $115.25 and a one year high of $177.00. The business’s 50 day simple moving average is $126.21 and its two-hundred day simple moving average is $133.55. The stock has a market capitalization of $53.19 billion, a P/E ratio of 20.93, a price-to-earnings-growth ratio of 1.97 and a beta of 0.95.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. During the same quarter last year, the business earned $1.40 earnings per share. The business’s revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio is currently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.